{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001799","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.652959+00:00","generated_at":"2026-05-24T03:30:53.894613+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aptose reports FY 2024 net loss of $25.4M; cash runway to April 2025","bullets":["Net loss $25.4M vs $51.2M in FY 2023; diluted EPS ($36.38) vs ($227.43).","Cash and equivalents $6.7M as of Dec 31, 2024; expect funding through April 2025.","TUS+VEN+AZA triplet TUSCANY trial advancing; 40mg achieved CRs; 80mg dosing started.","$1.5M of Hanmi debt converted to 409,063 common shares; Hanmi stake capped at 19.99%.","Regained Nasdaq minimum bid compliance; still not in compliance with $2.5M equity requirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001799","json":"https://secwatch.observer/filing/0001171843-25-001799.json","markdown":"https://secwatch.observer/filing/0001171843-25-001799.md","text":"https://secwatch.observer/filing/0001171843-25-001799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325001799/0001171843-25-001799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325001799/f8k_032825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:30:53.894613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}